{"id":{"repo_id":"portland-state","oai_identifier":"oai:pdxscholar.library.pdx.edu:open_access_etds-2108"},"canonical_url":"https://search.dev.ndltd.org/etd/portland-state/oai:pdxscholar.library.pdx.edu:open_access_etds-2108","repository":{"repo_id":"portland-state","name":"Portland State University","base_url":"https://pdxscholar.library.pdx.edu/do/oai/"},"display":{"title":"Developing Thyronamine Analog Pharmaceuticals Targeting TAAR1 to Treat Methamphetamine Addiction","abstract":"","abstract_html":null,"abstract_has_math":false,"creators":["Wahl, Troy Andrew"],"institution":null,"degree_name":"Doctor of Philosophy (Ph.D.) in Chemistry","degree_level":"Dissertation","degree_discipline":null,"degree_department":null,"school":null,"contributors":["David H. Peyton"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":null,"date_issued":"","date_published":null,"updated_at":"2026-07-27T20:31:59Z","subjects":["Methamphetamine abuse -- Treatment","Biogenic amines -- Receptors","Drug targeting -- Research","Chemicals and Drugs","Medicinal-Pharmaceutical Chemistry"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"https://pdxscholar.library.pdx.edu/open_access_etds/1109","outbound_label":"Repository record","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["David H. Peyton"]},{"key":"dc:creator","label":"Author","values":["Wahl, Troy Andrew"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"thesis:degree_level","label":"Degree Level","values":["Dissertation"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Doctor of Philosophy (Ph.D.) in Chemistry"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Methamphetamine abuse -- Treatment","Biogenic amines -- Receptors","Drug targeting -- Research","Chemicals and Drugs","Medicinal-Pharmaceutical Chemistry"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://pdxscholar.library.pdx.edu/open_access_etds/1109"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:title","label":"Title","values":["Developing Thyronamine Analog Pharmaceuticals Targeting TAAR1 to Treat Methamphetamine Addiction"]}]}],"canonical_facts":{"dc:contributor":["David H. Peyton"],"dc:creator":["Wahl, Troy Andrew"],"dc:identifier":["https://pdxscholar.library.pdx.edu/open_access_etds/1109"],"dc:subject":["Methamphetamine abuse -- Treatment","Biogenic amines -- Receptors","Drug targeting -- Research","Chemicals and Drugs","Medicinal-Pharmaceutical Chemistry"],"dc:title":["Developing Thyronamine Analog Pharmaceuticals Targeting TAAR1 to Treat Methamphetamine Addiction"],"thesis:degree_level":["Dissertation"],"thesis:degree_name":["Doctor of Philosophy (Ph.D.) in Chemistry"]},"updated_at":"2026-07-27T20:31:59Z"}